Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical reports developments in robotic-assisted minimally invasive care, centered on its da Vinci surgical systems, da Vinci 5, da Vinci SP, and Ion Endoluminal System. Company news commonly covers procedure volume, system placements, installed-base growth, instruments and accessories revenue, operating lease placements, and share repurchase activity.
Updates also include FDA clearances that expand indications for Intuitive platforms, such as cardiac procedures for da Vinci 5 and additional procedures for da Vinci SP. News about the company also reflects completed commercial expansion in Europe, including direct operations for da Vinci and Ion distribution in Southern European markets.
Intuitive (Nasdaq: ISRG) reported preliminary unaudited results: Q4 2025 revenue ~$2.87B (+19% YoY) and FY2025 revenue ~$10.06B (+21% YoY). Full‑year da Vinci procedures totaled ~3,153,000 (+18% YoY) and the company placed 1,721 da Vinci systems in 2025 (including 870 da Vinci 5); Q4 placements were 532 systems (303 da Vinci 5). Instruments & accessories revenue was ~$1.66B in Q4 and ~$6.02B for FY2025. Preliminary results include a $70M fourth‑quarter contribution to the Intuitive Foundation. The company expects da Vinci procedures +13%–15% in 2026. Results are unaudited and subject to final closing and audit.
Intuitive (NASDAQ: ISRG) announced that the U.S. Food and Drug Administration cleared the da Vinci Single Port (SP) surgical system on Dec 10, 2025 for use in inguinal hernia repair, cholecystectomy, and appendectomy.
The clearances expand SP’s U.S. indications beyond existing approvals in urology, colorectal, thoracic, and transoral procedures and build on prior international approvals in Europe, Japan, and Korea. The company highlights a supporting evidence base of more than 500 peer-reviewed publications and describes SP as enabling single-incision or natural-orifice access with three multi-jointed instruments and an articulating 3DHD endoscope.
Intuitive (Nasdaq: ISRG) reported Q3 2025 results for the quarter ended Sept 30, 2025. Revenue was $2.51B, up 23% year-over-year. Worldwide procedures (da Vinci + Ion) grew ~20%; da Vinci procedures +19% and Ion +52%. The company placed 427 da Vinci systems (240 da Vinci 5) and 50 Ion systems, growing the da Vinci installed base to 10,763 (+13%) and Ion to 954 (+30%).
GAAP net income was $704M ($1.95 diluted EPS); non-GAAP net income was $867M ($2.40). Repurchased 4.0M shares for $1.92B. Cash and investments ended at $8.43B, down $1.10B.
2025 outlook: da Vinci procedure growth ~17.0–17.5%; non-GAAP gross margin expected 67–67.5% (vs 69.1% in 2024) and non-GAAP OpEx growth 11–13%; tariffs cited as a margin headwind.
Intuitive (NASDAQ:ISRG) announced FDA clearance of a software update for the Ion endoluminal system on Oct 8, 2025. The release adds AI-driven navigation to address CT-to-body divergence and integrates advanced imaging, including tomosynthesis with standard 2D C-arm, to broaden access to real-time imaging during lung biopsies. Features will begin with a limited U.S. launch and a broader U.S. rollout is planned for 2026. As of June 30, 2025, more than 900 Ion systems were installed across 10 countries, and Intuitive is supporting clinical research involving >b>2,000 subjects.
Jupiter Endovascular (ISRG) closed an oversubscribed Series B financing that surpassed its $40 million target, led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor. Proceeds will fund completion of the SPIRARE II pivotal trial, commercialization preparation, and new TFX applications. The announcement follows an FDA 510(k) clearance last month for the Vertex Catheter with TFX and precedes presentation of first-in-human SPIRARE I results at TCT on October 26, 2025. SPIRARE II plans to enroll up to 145 patients at up to 25 U.S. and European sites.
Intuitive (Nasdaq: ISRG) has unveiled new software capabilities for its da Vinci 5 robotic surgery system, leveraging its enhanced computing power that is 10,000 times greater than the previous da Vinci Xi model. The update introduces three key features: Force Gauge, a visual indicator showing real-time force applied during surgery; In-Console Video Replay, allowing surgeons to review procedure moments without leaving the console; and Network CCM, enabling remote software updates.
The Force Gauge feature measures force within a 0-6.5 Newton range, with published data suggesting reduced force application during procedures. These FDA-cleared features aim to enhance surgical precision, efficiency, and patient outcomes while reducing administrative burden through remote updates.
Intuitive Surgical's (NASDAQ:ISRG) da Vinci 5® robotic surgical system has been launched across all MemorialCare hospitals in Southern California, marking a significant expansion of advanced surgical capabilities. The system features 10,000 times more computing power than its predecessor and introduces over 150 design enhancements.
Key improvements include next-generation 3D imaging, Force Feedback technology that reduces tissue pressure by up to 43% in preclinical trials, and enhanced ergonomics. More than 120 surgeons across MemorialCare's three hospitals are trained to perform procedures in nine specialties using da Vinci platforms.
Intuitive (NASDAQ: ISRG) reported strong Q2 2025 financial results with revenue reaching $2.44 billion, up 21% year-over-year. The company's worldwide da Vinci procedures grew 17%, with 395 new system placements bringing the total installed base to 10,488 systems, a 14% increase from the previous year.
Key highlights include GAAP net income of $658 million ($1.81 per diluted share) and non-GAAP net income of $798 million ($2.19 per diluted share). The company secured important regulatory approvals, including European MDR certification and Japanese clearance for its da Vinci 5 surgical system.
For 2025, Intuitive projects worldwide da Vinci procedure growth of 15.5% to 17% and expects non-GAAP operating expense growth of 10% to 14%.
Intuitive (NASDAQ:ISRG), the robotic surgery pioneer, demonstrated groundbreaking telesurgery capabilities at the Society of Robotic Surgery conference in Strasbourg, France. Two surgeons, Dr. Doug Stoddard in Georgia and Dr. Andrea Pakula in France, successfully performed a transatlantic demonstration using a dual console da Vinci 5 system with Force Feedback technology.
The demonstration showcased remote surgical control capabilities across 4,000 miles, enabling surgeons to collaborate and share control of surgical instruments. CEO Dave Rosa emphasized that while telesurgery shows promise for improving patient access to minimally invasive care, the company prioritizes patient safety and practical value over technological advancement.
The demonstrated telesurgery software remains in development and is not yet FDA-cleared or CE marked. Intuitive has facilitated nearly 17 million da Vinci procedures and trained approximately 90,000 surgeons over its 30-year history.
Intuitive (Nasdaq: ISRG) has received FDA clearance for its new Vessel Sealer Curved, an advanced bipolar electrosurgical instrument designed for use with multiport da Vinci systems. The instrument represents a significant advancement in surgical technology, featuring a unique curved tip and fully wristed design for enhanced precision in minimally invasive procedures.
The device is FDA-cleared for sealing blood vessels up to 7mm in diameter and is notably the first of Intuitive's advanced energy instruments approved for lymphatic vessel transection. The curved jaw design follows natural anatomical contours, improving visibility and control in tight spaces. This milestone comes as Intuitive celebrates its 30th year in robotic-assisted technology, with nearly 17 million da Vinci procedures performed to date.